Drug Profile
Research programme: advanced stem cell therapies - Ferrer Advanced Biotherapeutics /Histocell
Alternative Names: HC 016; Tissue engineering drugs - Ferrer/HistocellLatest Information Update: 28 Mar 2018
Price :
$50
*
At a glance
- Originator Ferrer; Histocell
- Class Stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Brain injuries; Cartilage disorders
Most Recent Events
- 28 Mar 2018 No recent reports of development identified for preclinical development in Brain injuries in Spain
- 28 Mar 2018 No recent reports of development identified for preclinical development in Cartilage-disorders in Spain
- 18 Feb 2014 Ferrer and Histocell agree to co-develop Advanced stem cell therapy in Spain for Cartilage disorders, brain and spinal cord injuries